Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonraybio CoTPE:6955 +1.11%66 EV-to-EBITDA is 19.03 as of Sep. 04, 2026, which is 49% below its 10-year median of 37.13. GuruFocus rates TPE:6955 with a GF Score™ of 66/100 and a GF Value™ of NT$151.96 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Bonraybio Co ranks worse than 64.66% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bonraybio Co's enterprise value is NT$2,501.9 Mil.
Bonraybio Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$131.4 Mil. Therefore, Bonraybio Co's EV-to-EBITDA for today is 19.03.
The historical rank and industry rank for Bonraybio Co's EV-to-EBITDA or its related term are showing as below:
TPE:6955'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 17.19 Med: 37.13 Max: 135.43
Current: 19.03
During the past 6 years, the highest EV-to-EBITDA of Bonraybio Co was 135.43. The lowest was 17.19. And the median was 37.13.
TPE:6955's EV-to-EBITDA is ranked worse than 64.66% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.26
vs TPE:6955: 19.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bonraybio Co's PE Ratio (TTM) for today is calculated as:
Bonraybio Co's share price for today is NT$100.00.
Bonraybio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3.511.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bonraybio Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6955 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Bonraybio Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonraybio Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonraybio Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bonraybio Co's EV-to-EBITDA falls into.
Bonraybio Co's current Enterprise Value is NT$2,501.9 Mil.
Bonraybio Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$131.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonraybio Co (TPE:6955) has a EV-to-EBITDA of 19.03 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bonraybio Co. This is 49% below median its historical median of 37.13. Over the past decade, Bonraybio Co's EV-to-EBITDA has ranged from 17.19 to 135.43. According to the industry distribution chart, Bonraybio Co ranks #333 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 64.7%.
Is Bonraybio Co's EV-to-EBITDA too high?
Bonraybio Co's current EV-to-EBITDA of 19.03 is 49% below median its 10-year median of 37.13. Over the past 10 years, this metric has ranged from a low of 17.19 to a high of 135.43. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.26. Bonraybio Co's value of 19.03 is 33.5% above this industry median. Based on the distribution chart, Bonraybio Co ranks #333 out of 515 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bonraybio Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonraybio Co's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bonraybio Co ranks #333 out of 515 companies for EV-to-EBITDA. This places Bonraybio Co in the lower half of its industry. The industry median EV-to-EBITDA is 14.26. Bonraybio Co's value of 19.03 is 33.5% above this benchmark. Historically, Bonraybio Co's own EV-to-EBITDA has ranged from 17.19 to 135.43 over the past decade. While the company's 10-year median is 37.13 vs. the industry median of 14.26, Bonraybio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.26, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonraybio Co's current EV-to-EBITDA of 19.03 is 33.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bonraybio Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonraybio Co's current EV-to-EBITDA is 19.03, which is 49% below median its own 10-year median of 37.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonraybio Co stock overvalued right now?
Based on GuruFocus' analysis, Bonraybio Co (TPE:6955) is currently considered Possible Value Trap. The stock's GF Value™ is NT$151.96, compared to a current price of NT$100.00 — trading 34.2% below its estimated fair value. The current EV-to-EBITDA is 19.03, which is 49% below median its 10-year median of 37.13 and 33.5% above the Medical Devices & Instruments industry median of 14.26. Bonraybio Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bonraybio Co (TPE:6955), the current EV-to-EBITDA is 19.03 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonraybio Co (TPE:6955) Overvalued in 2026?
Based on GuruFocus' analysis, Bonraybio Co stock appears to be undervalued.
The current stock price of NT$100.00 is trading 34.2% below its estimated GF Value™ of NT$151.96.
GuruFocus considers Bonraybio Co to be Possible Value Trap.
Key valuation signals for TPE:6955:
EV-to-EBITDA: 19.03 (49% below median its 10-year median of 37.13)
GF Value™: NT$151.96 vs. price of NT$100.00 (34.2% below fair value)
Industry Position: 33.5% above the Medical Devices & Instruments median (#333 of 515)
No single metric tells the full story. See the TPE:6955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonraybio Co Ltd engages in research, development, and manufacturing of vitro diagnostic devices. The firm produces semen quality analyzers and Semen Analysis Systems for the clinic.
66GF Score
Get the complete analysis for TPE:6955
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6955 has been successfully added to your 
